Breaking Down Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

Investors keen on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. will want to dig into the numbers: H1 2025 revenue was RMB 2.79 billion (down 1.3% year-over-year) and TTM revenue as of Sept 30, 2025 stood at RMB 5.38 billion, while gross profit margin plunged to 29.0% in H1 2025 from 35.3% a year earlier, net debt sits at around RMB 1.37 billion with cash of RMB 2.00 billion against total debt of RMB 3.37 billion (equity/book value RMB 13.58 billion; book value per share HKD 9.21), and market metrics show an enterprise value of HKD 17.41 billion, P/S near 2.9, P/B 1.28 and a trailing P/E of 37.32 on EPS of HKD 0.31 - juxtaposed with operating margin 11.62%, EBITDA margin 16.26%, strong operating cash flow (TTM) RMB 2.01 billion and free cash flow RMB 1.85 billion, a Piotroski F-Score of 8 and Altman Z-Score 3.18, yet facing notable declines in gross profit and attributable profit in H1 2025 and a falling net profit margin to 7.8% (TTM), so read on for a line-by-line breakdown of revenue, profitability, leverage, liquidity, valuation and the growth levers in CDMO and finished-dose segments that analysts peg to drive projected earnings growth of 16.5% and revenue growth of 7.9%.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Revenue Analysis

Shenzhen Hepalink reported mixed top-line signals through 2024-2025 with slight declines in reported revenues, modest revenue per head and a mid-cap market valuation that yields a P/S of 2.92. Key reported figures and short observations are summarized below.

• H1 2025 revenue: RMB 2.79 billion (down 1.3% vs H1 2024).
• TTM revenue as of 30-Sep-2025: RMB 5.38 billion (down 0.96% YoY).
• FY 2024 revenue: RMB 5.26 billion (down 3.17% vs FY 2023).
• Revenue per employee: ~RMB 2.80 million (total employees: 1,926).
• Price-to-Sales (P/S) ratio: 2.92.
• Market capitalization: HKD 17.20 billion (mid-cap range).

• Top-line trend: modest contraction across FY 2024 and TTM to Sep‑2025, with H1 2025 slightly negative vs prior-year H1.
• Operational productivity: revenue per employee (~RMB 2.80m) suggests moderate efficiency for a specialty pharmaceutical manufacturer; changes in headcount will materially affect this metric.
• Valuation context: P/S of 2.92 and HKD 17.20bn market cap place the stock in a mid-cap valuation band-investors will weigh growth outlook and margin trends against this multiple.

For more on shareholder composition, recent transactions and investor interest: Exploring Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Profitability Metrics

Key profitability metrics for Shenzhen Hepalink highlight a mixed picture: margins under pressure year-over-year in early 2025, but core operating profitability and EBITDA remain relatively healthy, and forward ROE shows potential uplift over the medium term.

• Gross profit margin (H1 2025): 29.0% (down from 35.3% in H1 2024; decline of 6.3 percentage points)
• Net profit margin (TTM): 7.80%
• EPS (TTM): HKD 0.31
• Price-to-Earnings (P/E): 37.32
• Operating margin: 11.62%
• EBITDA margin: 16.26%
• Forecasted ROE (next 3 years): 7.3%

• Implications for investors:
  • Gross margin compression suggests margin pressure from costs, pricing, or mix-monitor margin recovery across H2 2025.
  • Operating and EBITDA margins show the business still generates solid operational cash earnings relative to revenue.
  • Net margin and EPS imply modest absolute profitability; P/E of 37.32 signals the market is pricing in growth but with limited margin of safety.
  • Projected ROE of 7.3% over the next three years points to incremental improvement potential, but investors should weigh capital structure and reinvestment returns.

For more context on shareholder composition and buying trends, see: Exploring Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Debt vs. Equity Structure

• Cash and cash equivalents (as of 31 Mar 2025): RMB 2.00 billion
• Total debt (as of 31 Mar 2025): RMB 3.37 billion
• Net debt (Total debt - Cash): ~RMB 1.37 billion (net indebted)
• Equity (book value): RMB 13.58 billion
• Book value per share: HKD 9.21
• Debt-to-equity ratio: ~0.25
• Working capital: RMB 5.98 billion
• Altman Z-Score: 3.18 (low probability of financial distress)
• Net cash position per share: negative (liabilities exceed cash holdings)

• Conservative leverage: A 0.25 debt-to-equity suggests capacity to absorb shocks and fund growth without aggressive borrowing.
• Liquidity cushion: RMB 5.98 billion working capital and RMB 2.00 billion cash provide short-term flexibility despite net indebtedness.
• Credit risk perspective: Net debt of RMB 1.37 billion relative to RMB 13.58 billion equity keeps solvency metrics comfortable; Altman Z-Score (3.18) supports low bankruptcy risk.
• Per-share considerations: Book value per share (HKD 9.21) indicates a solid equity base, but a negative net cash position per share means investors should monitor cash generation and debt repayment progress.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Liquidity and Solvency

• Operating cash flow (TTM): RMB 2.01 billion
• Free cash flow (TTM): RMB 1.85 billion (after capital expenditure of RMB 168.21 million)
• Dividend payout ratio: 68.39%
• Piotroski F-Score: 8 (strong)

• The current ratio (current assets / current liabilities) is not directly reported here but can be inferred from the company's balance sheet items (cash, receivables, inventory vs. short-term debt and payables). An inferred current ratio above 1 would indicate adequate near-term liquidity; precise calculation requires checking the latest balance sheet figures.
• The quick ratio (current assets minus inventory, divided by current liabilities) similarly must be estimated from balance-sheet line items; this excludes inventory to reflect immediately liquid resources.

• Implication: Robust operating cash flow and positive free cash flow support dividend policy and reduce refinancing risk, but exact short-term liquidity cushions depend on current and quick ratios computed from the latest balance sheet.
• Action item for investors: verify current and quick ratios from the most recent financial statements to confirm short-term liquidity margins.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Valuation Analysis

• Market capitalization: HKD 17.41 billion
• Enterprise value (EV): HKD 17.47 billion
• P/S (Price-to-Sales): 2.96
• P/B (Price-to-Book): 1.28
• P/TBV (Price-to-Tangible Book Value): 1.64
• P/FCF (Price-to-Free Cash Flow): 9.43
• P/OCF (Price-to-Operating Cash Flow): 8.64

• EV-to-MarketCap proximity: EV (HKD 17.47B) is almost equal to Market Cap (HKD 17.41B), indicating low net debt or offsetting cash and debt positions.
• Cash-flow multiples (P/FCF 9.43; P/OCF 8.64) suggest the market is valuing cash generation more cheaply than many growth peers but still within reasonable range for pharmaceuticals.
• Book-value metrics (P/B 1.28; P/TBV 1.64) imply tangible assets are valued higher once intangibles are stripped out, pointing to meaningful intangible asset contribution to equity value.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Risk Factors

• Sharp earnings deterioration: Gross profit fell by 19.0% and profit attributable to equity holders declined by 36.4% in the first half of 2025, signaling acute operational or revenue-pressure events during the period.
• Compressing profitability: Net profit margin has trended down from 12.2% in 2022 to 7.80% on a trailing twelve months (TTM) basis, reflecting weaker bottom-line capture from revenue.
• Rising cost pressure: Gross profit margin dropped from 35.3% in 2024 to 29.0% in H1 2025, indicating margin squeeze potentially from higher input costs, pricing pressure, or mix shifts.
• Leverage and debt reliance: A net debt position of approximately RMB 1.37 billion points to dependence on debt financing and exposes the company to refinancing and interest-rate risks.
• Liquidity strain: The company reports a negative net cash position per share (liabilities exceed cash), which can limit operational flexibility and raise short-term funding risk.
• Modest expected returns: Analysts' consensus/management forecast implies a return on equity around 7.3% within three years, a relatively low level that may weigh on investor confidence and relative valuation.

• Operational risks: Continued margin erosion or prolonged revenue weakness could further depress profitability and cash generation.
• Financial risks: The net debt position and negative net cash per share increase vulnerability to interest-rate rises, covenant stress and refinancing needs.
• Market/valuation risks: Low forecast ROE and falling margins may compress multiples and raise the risk of valuation re-rating.
• Event risk: Any further one-off impairments, product-specific issues, or regulatory actions in the pharma sector could magnify earnings volatility.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) - Growth Opportunities

• Analysts' projections: earnings +16.5% p.a.; revenue +7.9% p.a.
• First half 2024 momentum: revenue RMB 2.837 billion (+4.59% YoY).
• Finished-dose products remain core: RMB 2,986.1 million in 2024 (~56.8% of Group revenue).
• API segment: revenue down 18.5% YoY, but gross profit margin improved to ~38.6% from -42.8% in 2023, indicating operational and pricing recovery.
• CDMO (Contract Development & Manufacturing Organization): sales RMB 1,033.8 million in 2024 (+6.9% YoY) with gross profit margin ~32.9%, providing diversification and higher-margin growth potential.

• Growth levers: ramping CDMO capacity and commercial finished-dose scale reduce single-segment dependency and enhance recurring revenue.
• Margin dynamics: API margin turnaround materially improves consolidated profitability despite lower API top-line.
• Execution risks to monitor: integration of CDMO projects, R&D pipeline conversion, and pricing/regulatory environment.